Affordable Access

Publisher Website

Emerging Safety Issues with Imatinib and Other Abl Tyrosine Kinase Inhibitors

Authors
Journal
Clinical Lymphoma & Myeloma
1557-9190
Publisher
Elsevier - CIG Media Group LP
Volume
7
Identifiers
DOI: 10.3816/clm.2007.s.010
Keywords
  • Chronic Myeloid Leukemia
  • Gastrointestinal Stromal Tumors
  • Side Effects
Disciplines
  • Medicine

Abstract

Abstract Imatinib and other Abl tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have significantly improved the outcome of patients with chronic myeloid leukemia. Imatinib and dasatinib are currently Food and Drug Administration (FDA) approved, and nilotinib is expected to gain FDA approval soon. In addition, several other Abl TKIs are being evaluated in various clinical trials. Imatinib has also shown efficacy in the therapy of gastrointestinal stromal tumors, Philadelphia chromosome–positive acute lymphocytic leukemia and hypereosinophilic syndrome. Because of their efficacy, more patients will receive Abl TKIs for a longer period of time. Imatinib was FDA approved after a short follow-up because of its exceptional efficacy and safety profile. The most common adverse events reported included fluid retention, fatigue, diarrhea, and muscle cramps. With longer follow-up, issues related to the long-term use of imatinib have been discussed. Our aim is to review the emerging safety issues of Abl TKIs after a longer follow-up.

There are no comments yet on this publication. Be the first to share your thoughts.